Group 1: Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered approaches, aiming to enhance the efficiency of clinical trials in China [1] - As of Q3 2025, the company achieved a revenue of CNY 219 million, representing a year-on-year growth of 9.84% [1] - For the first three quarters of 2025, total revenue reached CNY 609 million, with a net profit of CNY 87.38 million, up 20.92% year-on-year [2] Group 2: Financial Performance - The net profit for Q3 2025 was CNY 33.23 million, showing a significant increase of 91.60% year-on-year [2] - The company’s non-recurring net profit for the same period was CNY 31.13 million, reflecting a growth of 120.72% [2] - Cumulative service projects exceeded 4,200, with 2,538 active projects and a workforce of 4,271 employees [2] Group 3: Market Position and Strategy - Proris has established partnerships with major pharmaceutical companies, including the top 10 global pharmaceutical firms, enhancing its service capabilities in innovative drug projects [3] - The company is focused on digitalization and smart technology to improve clinical trial management efficiency [3] - The domestic innovative drug market is experiencing rapid growth, with 76 new drugs approved in 2025, marking a historical high [2] Group 4: Future Outlook - The company plans to continue its recruitment and training efforts to align with market demands and regulatory standards, ensuring a robust talent pipeline for future growth [3] - The innovative drug industry in China is expected to positively impact the clinical research outsourcing business, driven by policy, funding, and technology advancements [2]

Group 1 - The core point of the news is that Proprius (Shanghai) Pharmaceutical Technology Development Co., Ltd. experienced a stock price decline of 5.06%, trading at 66.26 CNY per share, with a total market capitalization of 5.235 billion CNY as of the report date [1] - Proprius was established on February 22, 2013, and went public on May 17, 2022, focusing on technology development, transfer, consulting, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] Group 2 - From the perspective of major fund holdings, the Chuangjin Hexin Fund has a significant position in Proprius, holding 121,000 shares in its Chuangjin Hexin Health Mixed A Fund, which represents 4.56% of the fund's net value, ranking it as the tenth largest holding [2] - The Chuangjin Hexin Health Mixed A Fund, established on January 26, 2022, has a current scale of 47.4529 million CNY, with a year-to-date return of 9.74% and a one-year return of 38.81%, ranking 1027 out of 8847 and 3324 out of 8094 respectively [2] - The fund manager, Pi Jinsong, has been in the position for 7 years and 80 days, managing assets totaling 900 million CNY, with the best return during his tenure being 119.78% and the worst being -49.36% [2]

Investment Rating - The report gives a "Buy" rating for the company with a target price of 93 yuan [1][12]. Core Insights - The company is positioned as a leader in the SMO (Site Management Organization) industry, benefiting from the growth in clinical trial demand, industry consolidation, and the empowerment of AI technology, indicating a new growth cycle ahead [6][7]. - The SMO industry is experiencing rapid development, with a projected annual growth rate of 15-20% for clinical trials in China over the next 3-5 years, driven by increased investment in innovative drug research [8][43]. - The company has established a strong competitive advantage through its extensive project experience, comprehensive quality control systems, and a nationwide execution network [10][52]. Financial Summary - Total revenue is projected to reach 804 million yuan in 2024, with a year-on-year growth of 5.7%, and is expected to grow to 1.305 billion yuan by 2027 [2]. - The net profit attributable to shareholders is forecasted to be 106 million yuan in 2024, with a decline of 21%, but is expected to recover to 198 million yuan by 2027, reflecting a growth of 24.4% [2]. - Earnings per share (EPS) are expected to increase from 1.35 yuan in 2024 to 2.51 yuan in 2027 [2]. Industry Overview - The SMO industry is crucial for clinical research, managing all non-medical judgment tasks in clinical trials, which enhances the efficiency of drug development [25][29]. - The number of clinical trials in China is expected to grow significantly, with 4,900 trials projected for 2024, marking a 13.9% increase from the previous year [33][39]. - The market share of leading SMO companies is anticipated to increase, with the top five players currently holding about 25-30% of the market, similar to trends observed in Japan [9][46]. Competitive Advantages - The company has a robust project experience, having managed over 4,200 projects, and maintains a strong presence in various disease areas, particularly oncology [10][57]. - The quality control system is well-established, ensuring high-quality project delivery and fostering strong client trust [63]. - The integration of AI technology is expected to enhance operational efficiency, with the company's AI-driven solutions improving information processing efficiency by 90% [11][62].

证券日报网讯1月15日，普蕊斯（301257）在互动平台回答投资者提问时表示，截至2025年12月31日收 盘，公司股东总数为6759户。 ...

Core Viewpoint - The market experienced a slight decline on January 14, with the Shanghai Composite Index down by 0.31%. However, the total margin financing balance increased to 26,982.31 billion yuan, reflecting a rise of 152.38 billion yuan from the previous trading day [1]. Margin Financing Overview - As of January 14, the margin financing balance in the Shanghai market was 13,513.10 billion yuan, up by 82.09 billion yuan; in the Shenzhen market, it was 13,376.36 billion yuan, increasing by 68.55 billion yuan; and in the Beijing Stock Exchange, it reached 92.85 billion yuan, up by 1.74 billion yuan. The combined margin financing balance for Shanghai, Shenzhen, and Beijing was 26,982.31 billion yuan, an increase of 152.38 billion yuan [1]. - Among the industries tracked by Shenwan, 22 sectors saw an increase in margin financing, with the computer industry leading with an increase of 39.64 billion yuan, followed by the communication and public utilities sectors, which increased by 16.97 billion yuan and 16.93 billion yuan, respectively [1]. Individual Stock Performance - A total of 1,961 stocks experienced an increase in margin financing, accounting for 52.02% of the total. Among these, 535 stocks had a margin financing increase of over 5%. The stock with the highest increase in margin financing was Puris, with a latest margin financing balance of 1.20 billion yuan, reflecting a 228.57% increase from the previous trading day, and its stock price rose by 14.70% [1]. - Other notable stocks with significant increases in margin financing included Zhisheng Information and Ruifeng New Materials, with increases of 117.49% and 77.12%, respectively [1]. Top Gainers and Losers in Margin Financing - The top 20 stocks with the highest increase in margin financing averaged a rise of 7.00%, with Jia Yuan Technology, Hanshuo Technology, and Nuo Si Ge leading with increases of 20.00%, 20.00%, and 19.25%, respectively [2]. - Conversely, the stocks with the largest decreases in margin financing included Feike Electric, which saw a decline of 42.15%, and other notable declines were recorded by Lifan Holdings and Shisheng Intelligent, with decreases of 27.19% and 23.79%, respectively [5].

Core Viewpoint - The stock price of Pruis (301257.SZ) has experienced an abnormal fluctuation, with a cumulative increase of over 30% in closing prices over two consecutive trading days [1] Company Information - Pruis confirmed that there are no corrections or supplements needed for previously disclosed information [1] - The company has not identified any significant undisclosed information in recent media reports that could have impacted its stock price [1] - The company's recent operational situation is normal, and there have been no significant changes in the internal or external operating environment [1] Shareholder Actions - Shareholder Huiqiao Hongjia plans to reduce its holdings by no more than 0.71% of shares [1] - Shareholder Zhang Jing intends to reduce its holdings by no more than 1.16% of shares [1]

2、公司股东张晶持有公司股份916,826股，占本公司总股本比例1.1605%。股东张晶计划自本公告发布 之日起3个交易日后的3个月内以大宗交易方式和/或以集中竞价交易方式减持本公司股份不超过916,826 股（占本公司总股本比例1.1605%）。 格隆汇1月14日丨普蕊斯(301257.SZ)公布，1、普蕊斯（上海）医药科技开发股份有限公司股东上海弘 甲私募基金管理有限公司－宁波汇桥弘甲创业投资合伙企业（有限合伙）（简称"汇桥弘甲"）持有公司 股份557,320股，占本公司总股本比例0.7054%。汇桥弘甲计划自本公告发布之日起3个交易日后的3个月 内以大宗交易方式和/或以集中竞价交易方式减持本公司股份不超过557,320股（占本公司总股本比例 0.7054%）。 ...

公司持股1.16%的股东张晶计划3个交易日后的3个月内，以大宗交易方式或集中竞价交易方式，减持公 司股份不超过91.68万股(占公司总股本的1.16%)。 人民财讯1月14日电，普蕊斯（301257）1月14日公告，公司持股0.71%的股东汇桥弘甲计划3个交易日 后的3个月内，以大宗交易方或集中竞价交易方式，减持公司股份不超过55.73万股(占公司总股本的 0.71%)。 ...

每经AI快讯，普蕊斯1月14日晚间发布公告称，股东上海弘甲私募基金管理有限公司－宁波汇桥弘甲创 业投资合伙企业（有限合伙）持有公司股份约56万股，占公司总股本比例为0.7054%。汇桥弘甲计划自 本公告发布之日起3个交易日后的3个月内以大宗交易方式和/或以集中竞价交易方式减持公司股份不超 过约56万股（占公司总股本比例为0.7054%）。 （记者 张明双） 公司股东张晶持有公司股份约92万股，占公司总股本比例为1.1605%。股东张晶计划自本公告发布之日 起3个交易日后的3个月内以大宗交易方式和/或以集中竞价交易方式减持公司股份不超过约92万股（占 公司总股本比例为1.1605%）。 每经头条（nbdtoutiao）——海利生物增值9倍并购的企业，估值8个月"腰斩"，其第一大客户竟是尚未 成立的公司，离奇的事还不少…… ...

普蕊斯(301257.SZ)公告称，公司股票交易价格连续两个交易日收盘价涨幅偏离值累计超过30%，属于股 票交易异常波动情形。经核实，公司前期披露的信息不存在需要更正、补充之处，未发现近期公共传媒 报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息，公司近期经营情况正常，内外 部经营环境未发生重大变化。股东汇桥弘甲拟减持不超0.71%股份、股东张晶拟减持不超1.16%股份。 ...